Adherence to strategies: uptake of rapid antigen test (over 13‐week · school staff
1 finding from 1 review
Rapid sodium increase · chronic non‐hypovolaemic hypotonic hyponatraemia
Vasopressin receptor antagonists probably leads to higher rapid sodium increase compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
1 finding from 1 review
Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Wessel 1995: Mean syllable duration during rapid‐syllable repetition task. Scale from: 1 to 500. Shorter durations are better. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
no estimate extracted
4 participants
Very low
Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) showed no clear difference in global state: non‐responders to the first injection compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (low certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects: movement disorders ‐ EPS during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: movement disorders ‐ EPS during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower specific behaviour: Agitation ‐ clinically important change (PANSS… compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).
1 finding from 1 review
Global state: CGI‐S change score up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Adverse effects: one or more adverse effects during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse effects during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (very low certainty).
1 finding from 1 review
Somnolence · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower adverse effects: somnolence during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes repeated need for tranquillisation ‐ needing additional injections… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes specific behaviour: Agitation ‐ clinically important change (PANSS… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower global state: non‐responders to the first injection compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review